Drug intelligence / Profile preview

deriglidole

Development stage: Discontinued
Lead developer: Sanofi
Modality: Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Deriglidole is a small molecule drug classified as an imidazole and indole derivative. It acts as a potent and selective peripheral alpha-2 adrenergic receptor antagonist. Deriglidole was developed for the treatment of type 2 diabetes mellitus due to its ability to inhibit alpha-2 adrenoceptors and ATP-sensitive potassium channels in pancreatic beta cells, leading to increased insulin release. The effects on alpha-2 adrenoceptors are stereoselective, but not on ATP-sensitive K+ channels. Clinical development reached phase II before being discontinued[1][2][5].

Other names: deriglidoleSL 86-0715SL86-0715SL-86-0715

Targets

ADRA2A (α2A)

Beyond the preview

Go deeper on deriglidole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on deriglidole.

Explore the full profile